As advocates for individuals and families affected by asbestos-related diseases, our mesothelioma attorneys closely monitor every development that could impact treatment options, legal rights, or day-to-day support for the mesothelioma community. August and September 2025 delivered meaningful news on all three fronts: a significant jury verdict against Johnson & Johnson in Massachusetts, momentum behind a new targeted drug, a global Phase III trial to watch, and fresh federal activity on asbestos risk management. Below, we break down what each update means in plain English and explain how it may impact your case or care plan.
1) Massachusetts Jury Returns a $42.6 Million Talc, Mesothelioma Verdict: What It Means
On July 29, and then publicly reported in early August, a Massachusetts jury ordered J&J to pay $42.6 million to a mesothelioma patient who used talc-based Baby Powder for decades. The verdict adds to the body of talc and asbestos trials, where jurors have concluded that asbestos contamination in talc can cause mesothelioma and that consumers were not adequately warned. J&J has indicated it will appeal, as it has in other cases. Appeals can take time, and outcomes vary. Still, a verdict of this magnitude in a Massachusetts court sends a strong signal about how juries here may evaluate causation and corporate knowledge evidence in talc and mesothelioma claims.